跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Amphiregulin
首页
药物
Amphiregulin
Amphiregulin
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
MATERIALS AND METHODS FOR PERFORMING HISTOCHEMICAL ASSAYS FOR HUMAN PRO-EPIREGULIN AND AMPHIREGULIN
EP 3514174 B1
申请人: VENTANA MED SYST INC
优先权: 2015
EP
US
WO
11 件公开
AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION, FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME
EP 3816285 A4
申请人: BIONEER CORP
优先权: 2018
CN
EP
US
WO
8 件公开
Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
EP 1449538 A1
申请人: MAX PLANCK GESELLSCHAFT
优先权: 2003
EP
US
5 件公开
Method for predicting the response to a treatment
US 7700299 B2
申请人: HOFFMANN LA ROCHE
优先权: 2005
CN
US
5 件公开
PREDICTION OF RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR-DIRECTED THERAPIES USING EPIREGULIN AND AMPHIREGULIN
EP 4217393 A1
申请人: VENTANA MED SYST INC
优先权: 2020
CN
EP
US
WO
4 件公开
AGENTS FOR USE IN THE THERAPEUTIC OR PROPHYLACTIC TREATMENT OF MYOPIA OR HYPEROPIA
EP 3070101 A1
申请人: UNIVERSITÄT HEIDELBERG
优先权: 2015
CN
EP
US
4 件公开
Cystic lymphangioma treatment drug
US 12698324 B2
申请人: NATIONAL UNIV CORPORATION UNIV OF TOYAMA
优先权: 2020
EP
US
WO
4 件公开
Amphiregulin as a Protective Agent in Acute Hepatic Injury
US 2008064629 A1
申请人: AVILA ZARAGOZA MATIAS ANTONIO
优先权: 2004
CN
EP
US
3 件公开
USE OF AMPHIREGULIN (AREG) IN METHODS OF TREATING VASCULAR HYPERPERMEABILITY
US 20260216290 A1
申请人: INST NAT SANTE RECH MED
优先权: 2023
EP
US
WO
3 件公开
Methods for treating lung cancers
US 8138167 B2
申请人: NAKAMURA YUSUKE
优先权: 2006
CN
US
3 件公开
第 1 / 4 页
上一页
下一页
药物
反馈